Halozyme Therapeutics Inc Stock Ownership - Who owns Halozyme Therapeutics?

Insider buying vs selling

Have Halozyme Therapeutics Inc insiders been buying or selling?
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2023-04-1810,000$36.00
Michael J. LabarreSVP CHIEF TECHNICAL OFFICER2023-04-1810,000$18.41
Helen TorleyPRESIDENT AND CEO2023-03-0910,000$14.66
Helen TorleyPRESIDENT AND CEO2023-03-0910,000$42.73
Helen TorleyPRESIDENT AND CEO2023-03-0810,000$14.66
Helen TorleyPRESIDENT AND CEO2023-03-0810,000$43.26
Helen TorleyPRESIDENT AND CEO2023-03-0710,000$14.66
Helen TorleyPRESIDENT AND CEO2023-03-0710,000$45.47
Jeffrey William HendersonDirector2023-03-0110,000$47.71
Jeffrey William HendersonDirector2023-02-2810,000$48.51

1 of 7

HALO insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when HALO insiders and whales buy or sell their stock.

HALO Shareholders

What type of owners hold Halozyme Therapeutics Inc stock?
Randal J. Kirk20.23%26,633,924$884.25MInsider
Blackrock Inc13.78%18,145,852$602.44MInstitution
Vanguard Group Inc10.27%13,519,639$448.85MInstitution
Artisan Partners Limited Partnership5.31%6,992,189$232.14MInstitution
State Street Corp4.52%5,954,775$197.70MInstitution
Snyder Capital Management L P3.26%4,295,184$142.60MInstitution
Gregory Ian Frost2.77%3,641,380$120.89MInsider
Jpmorgan Chase Co2.68%3,522,776$116.96MInstitution
Invesco Ltd2.65%3,491,177$115.91MInstitution
Macquarie Group Ltd2.43%3,200,481$106.26MInstitution

1 of 3

HALO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
HALO78.03%21.97%Net SellingNet Selling
PCVX80.84%19.16%Net SellingNet Selling
DNLI55.65%44.35%Net SellingNet Buying
TGTX54.98%45.02%Net Selling
ACAD70.81%29.19%Net BuyingNet Buying

Halozyme Therapeutics Stock Ownership FAQ

Who owns Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ: HALO) is owned by 92.96% institutional shareholders, 26.18% Halozyme Therapeutics insiders, and 0.00% retail investors. Randal J. Kirk is the largest individual Halozyme Therapeutics shareholder, owning 26.63M shares representing 20.23% of the company. Randal J. Kirk's Halozyme Therapeutics shares are currently valued at $884.25M.

If you're new to stock investing, here's how to buy Halozyme Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.